Premium
Annular atrophic lichen planus induced by anti‐HER2 antibodies
Author(s) -
Chawla Sumir,
Turner Nicholas,
Terlizzo Monica,
Heelan Kara
Publication year - 2021
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.13501
Subject(s) - pertuzumab , medicine , trastuzumab , docetaxel , monoclonal antibody , human epidermal growth factor receptor 2 , cancer , breast cancer , oncology , dermatology , antibody , immunology
Abstract Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER‐2) and are increasingly being utilised in the management of HER2‐positive breast cancer, having been demonstrated to improve progression‐free survival in conjunction with docetaxel. We present a rare presentation of a lichenoid drug eruption, in an annular atrophic variant, in a 35‐year‐old woman after initiation of HER2‐inhibitor (pertuzumab and trastuzumab) therapy for metastatic breast cancer.